Panbela Therapeutics Overview
Latest ROE for Panbela Therapeutics: 153.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow153.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Panbela Therapeutics posts a ROE of 153.59%. That is above the Technology sector average of 47.48%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Technology stocks, a ROE near 47.48% is typical. Panbela Therapeutics's 153.59% is higher that level. That is roughly 223.5% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Panbela Therapeutics's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 153.59%; use YoY and peer views to separate noise from signal.
Context for PBLA's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 47.48%), and (3) consistency with growth and profitability. This page covers the first two; Panbela Therapeutics's other metric pages and overview cover the third.
Judging Panbela Therapeutics against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in ROE easier to interpret. Start with 153.59% here, then scan peer and history charts to see if the gap is persistent.
